Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Streams: Advanced Therapies, Biomedical Engineering, Cancer
Nick Shah is a scientist and leader with extensive experience discovering novel therapies for unmet medical needs. He is currently the head of quantitative biology at Nura Bio, where the team is working to discover novel therapies to halt neurological disease.
Previously, Nick was the head of in-vitro pharmacology at DICE Therapeutics, where the team discovered DC-806 (PhI for psoriasis) and had a successful IPO. Nick was an early scientist at Flexus Biosciences and helped discover Linrodostat (PhIII for cancer), driving an acquisition by BMS. He also was a project lead at RAPT Therapeutics, where the team discovered FLX475 (PhII for cancer) and RPT193 (PhII for atopic dermatitis, PhI for asthma).
As a volunteer, Nick advises early-stage startup founders through Creative Destruction Lab and Springboard. He serves as a judge and career panelist for the BioGENEius Challenge and is a member of the California Life Sciences Racial and Social Equity Committee.
Nick completed his PhD at the University of Toronto and a postdoctoral fellowship at Stanford University.